Natural fungal products could offer potential Alzheimer's therapy

February 27, 2014 by Brendan M. Lynch, University of Kansas
Natural fungal products could offer potential Alzheimer’s therapy

A team of researchers at the University of Kansas, including T. Chris Gamblin, associate professor of molecular biosciences, and Berl Oakley, Irving S. Johnson Distinguished Professor of Molecular Biology, has shown that some fungal natural products can inhibit buildup of tau—a protein linked to Alzheimer's disease and other neurodegenerative diseases.

"Tau is a protein that is produced by the body," said Gamblin. "It's found primarily in neurons in the normal brain where it helps them maintain their shape and function. In Alzheimer's disease, through a mechanism we don't quite understand, is changed in a way that causes it to start clumping together with other tau molecules, forming string-like fibrils that accumulate into the pathological structure in Alzheimer's disease called 'neurofibrillary tangles.'"

Along with Clay Wang of the University of Southern California, Gamblin tested 17 natural fungal products, most of which had similar structures to compounds seen by previous researchers to hinder tau formation.

"Because fungi have historically been a rich source of biologically useful compounds, we thought it would be worth screening them to determine their activity," said Gamblin. "We used advanced genetic techniques to get the fungus to overproduce many, many different types of natural products so we could purify and identify them."

Of the 17 natural products, the researchers discovered three that were effective in inhibiting tau accumulation: 2,ω-dihydroxyemodin, asperthecin and asperbenzaldehyde.

Their findings were published recently in Planta Medica, a leading international peer-reviewed journal in the field of medicinal plants and natural product research.

"All three of them did block the aggregation of tau 100 percent as far as we can tell," said Gamblin. "Some of them took very high concentrations to do so though."

To test the in vitro, the researchers used a fatty acid to induce tau fibril formation by mixing the protein and fatty acid together either with or without a compound. Then they employed a filter trap assay "very similar to taking the material and pouring it over a sieve-like material or filter," according to Gamblin.

The filter trapped the large fibrils while individual proteins passed through the filter. Next, the investigators used electron microscopy—using a beam of electrons in place of light to a magnification in the hundreds of thousands—to visualize fibrils too small to be seen by conventional light microscopy.

"The biggest challenge for us was getting the filter trap to work reproducibly and consistently so we could be confident in our results," Gamblin said.

The KU researcher said that asperbenzaldehyde's ability to block tau formation was especially exciting, because no one before has identified a similarly structured molecule as a tau fibril inhibitor.

"Asperbenzaldehyde is also a precursor to a large class of molecules that help inhibit fatty acid oxidation," said Gamblin. "We can make the fatty acid oxidation inhibitors in two chemical steps using asperbenzaldehyde as the starting material, where it would take 16 steps if starting from scratch. It's interesting that people believe that inhibiting fatty acid oxidation in Alzheimer's patients may also have therapeutic benefit."

Gamblin said that there are two next steps to seeing if these natural compounds could become therapies for humans living with Alzheimer's disease and related disorders.

"The first would be to test the compounds on living cells or model organisms like fly or mouse models of Alzheimer's disease to see if they can prevent tau fibril formation in a cell or neuron," he said. "This is something we are currently working on. The second step would be to collaborate with a medicinal chemist to change the molecules in very specific ways to try to enhance their potency."

Explore further: Brain cell activity regulates Alzheimer's protein

Related Stories

Brain cell activity regulates Alzheimer's protein

February 26, 2014
Increased brain cell activity boosts brain fluid levels of a protein linked to Alzheimer's disease, according to new research from scientists at Washington University School of Medicine in St. Louis.

Fluorescent compounds allow clinicians to visualize Alzheimer's disease as it progresses

September 18, 2013
What if doctors could visualize all of the processes that take place in the brain during the development and progression of Alzheimer's disease? Such a window would provide a powerful aid for diagnosing the condition, monitoring ...

Newly identified antibodies effectively treat Alzheimer's-like disease in mice

September 26, 2013
Alzheimer's disease is characterized by the accumulation of particular toxic proteins in the brain that are believed to underlie the cognitive decline in patients. A new study conducted in mice suggests that newly identified ...

Potential biomarkers for the diagnosis of Alzheimer's disease

January 31, 2014
Researchers identify abnormal expression of genes, resulting from DNA relaxation, that can be detected in the brain and blood of Alzheimer's patients.

New Alzheimer's research suggests possible cause: The interaction of proteins in the brain

June 19, 2013
For years, Alzheimer's researchers have focused on two proteins that accumulate in the brains of people with Alzheimer's and may contribute to the disease: plaques made up of the protein amyloid-beta, and tangles of another ...

Stress-related protein speeds progression of Alzheimer's disease

September 4, 2013
A stress-related protein genetically linked to depression, anxiety and other psychiatric disorders contributes to the acceleration of Alzheimer's disease, a new study led by researchers at the University of South Florida ...

Recommended for you

New neuron-like cells allow investigation into synthesis of vital cellular components

January 22, 2018
Neuron-like cells created from a readily available cell line have allowed researchers to investigate how the human brain makes a metabolic building block essential for the survival of all living organisms. A team led by researchers ...

Finding unravels nature of cognitive inflexibility in fragile X syndrome

January 22, 2018
Mice with the genetic defect that causes fragile X syndrome (FXS) learn and remember normally, but show an inability to learn new information that contradicts what they initially learned, shows a new study by a team of neuroscientists. ...

Epilepsy linked to brain volume and thickness differences

January 22, 2018
Epilepsy is associated with thickness and volume differences in the grey matter of several brain regions, according to new research led by UCL and the Keck School of Medicine of USC.

Research reveals atomic-level changes in ALS-linked protein

January 18, 2018
For the first time, researchers have described atom-by-atom changes in a family of proteins linked to amyotrophic lateral sclerosis (ALS), a group of brain disorders known as frontotemporal dementia and degenerative diseases ...

Fragile X finding shows normal neurons that interact poorly

January 18, 2018
Neurons in mice afflicted with the genetic defect that causes Fragile X syndrome (FXS) appear similar to those in healthy mice, but these neurons fail to interact normally, resulting in the long-known cognitive impairments, ...

How your brain remembers what you had for dinner last night

January 17, 2018
Confirming earlier computational models, researchers at University of California San Diego and UC San Diego School of Medicine, with colleagues in Arizona and Louisiana, report that episodic memories are encoded in the hippocampus ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.